dotlah! dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
Social Links
  • zedreviews.com
  • citi.io
  • aster.cloud
  • liwaiwai.com
  • guzz.co.uk
  • atinatin.com
0 Likes
0 Followers
0 Subscribers
dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
  • Science
  • Technology

Everest Medicines To Develop, Commercialize EDDC’s Small Molecules As Potential COVID-19 Oral Antiviral Treatments

  • January 24, 2022
Total
0
Shares
0
0
0

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), and Singapore’s Experimental Drug Development Centre (“EDDC”) today announced a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop, manufacture and commercialize EDDC’s series of viral 3C-like (“3CL”) protease inhibitors as potentially best-in-class COVID-19 oral antiviral treatments. EDDC is Singapore’s national platform for drug discovery and development and is hosted by the Agency for Science, Technology and Research (“A*STAR”).

Under the terms of the agreement, Everest will obtain exclusive global rights to EDDC’s series of 3CL protease inhibitors that have demonstrated potent in-vitro activity against SAR-CoV-2 (the virus that causes COVID-19) and its variants, as well as other coronaviruses such as MERS. Everest has full rights to sub-license the drug further and will receive full technology transfer.

The lead compound is EDDC-2214, a novel and potent SARS-CoV-2 3CL protease inhibitor, which Everest will develop as an oral antiviral COVID-19 therapy. The main protease in SARS-CoV-2 is the 3CL protease. Compared to several other oral COVID-19 antivirals, EDDC-2214 exhibits better in-vitro potency and pre-clinical oral bioavailability. Clinical trials evaluating EDDC-2214 are expected to begin later this year.

“EDDC-2214 and future potential 3CL protease inhibitors are impactful new assets that complement our existing COVID-19 vaccine program,” said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. “We want to offer a package against COVID-19 that has both preventative vaccines and conveniently administered infection treatments. This is a prime example of the innovative risk-sharing relationship Everest is bringing about globally. We intend to bring the drug candidate quickly and efficiently through clinical trials, in order to deliver this novel oral antiviral treatment to patients during this time of limited therapeutic options.”

EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. EDDC has already been engaged in several public-private efforts to develop COVID-19 diagnostics and therapeutics. The Centre has collaborated with international partners and brought therapeutics and vaccines from research into clinical trials. In response to the global outbreak of the H1N1 influenza A virus (“H1N1”), EDDC (via its legacy units, ETC and D3) worked with public and private partners to successfully develop Singapore’s first H1N1 influenza vaccine showing favorable immunogenicity. Separately, EDDC supported the development of a monoclonal antibody against the dengue virus, named VIS513, in collaboration with a US biotech company Visterra Inc.

“This agreement with Everest positions us to harness the full potential of EDDC-2214 with the potential to deliver it to patients globally,” said Prof. Damian O’Connell, MD, PhD, Chief Executive Officer of EDDC. “Our team believes in the determination and ability of Everest to advance potentially best-in-class COVID-19 and pan-coronavirus therapeutics, and we are delighted to partner with Everest to make our joint vision a reality.”

Under the terms of the transaction, EDDC will receive an initial upfront payment and downstream clinical and commercial milestone payments, as well as typical royalties on net sales of products.

Everest is committed to ensure that any therapeutics developed for COVID-19 will be accessible and affordable globally.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of ten potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com.

About The Experimental Drug Development Centre (EDDC)

The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions.

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Total
0
Shares
Share
Tweet
Share
Share
Related Topics
  • A*STAR
  • COVID-19
  • EDDC
  • Everest Medicines
dotlah.com

Previous Article
people-wearing-face-mask-julian-wan-DWaC44FUV5o-unsplash
  • Cities
  • People

How to Detox While Living in a Polluted City

  • January 21, 2022
View Post
Next Article
  • Technology

Techblazer Awards Recognises 14 Organisations For Tech Innovation As Singapore Tech Sector Continues To Flourish

  • January 24, 2022
View Post
You May Also Like
View Post
  • Gears
  • Technology

Meet Samsung Galaxy Tab S11 Series: Packing Everything You Expect From a Premium Tablet

  • Dean Marc
  • September 4, 2025
View Post
  • Technology

Malaysia’s ‘ASEAN Shenzhen’ needs some significant legal reform to take off — here’s how

  • dotlah.com
  • August 25, 2025
View Post
  • Gears
  • Technology

Samsung Electronics Debuts Odyssey G7 Monitors, Showcasing Top Games on Its Displays at Gamescom 2025

  • Dean Marc
  • August 20, 2025
View Post
  • Artificial Intelligence
  • Technology

Thoughts on America’s AI Action Plan

  • Dean Marc
  • July 24, 2025
View Post
  • Technology

ESWIN Computing launches the EBC77 Series Single Board Computer with Ubuntu

  • dotlah.com
  • July 17, 2025
View Post
  • Gears
  • Technology

Samsung Galaxy Z Fold7: Raising the Bar for Smartphones

  • Dean Marc
  • July 9, 2025
View Post
  • Cities
  • Technology

Meralco PowerGen’s PacificLight starts up 100 MW fast-response plant in Singapore

  • dotlah.com
  • June 20, 2025
View Post
  • Technology

Apple services deliver powerful features and intelligent updates to users this autumn

  • Dean Marc
  • June 12, 2025


Trending
  • 1
    • Lah!
    UOB Asset Management Launches First Sustainable Bond Fund Focused On Impact Investing And Stable Income For Retail Investors
    • March 29, 2020
  • 2
    • Society
    How Contagious Is The Wuhan Coronavirus And Can You Spread It Before Symptoms Start?
    • January 30, 2020
  • 3
    • Science
    GIS, NUS, And Novo Nordisk Team Up To Study Non-alcoholic Fatty Liver Disease In Asian Populations
    • March 12, 2020
  • 4
    • Cities
    • Lah!
    SNDGO And NTUC Sign MOU To Enhance Workers’ Digital Skills And Spur Co-Creation Of Smart Nation Initiatives
    • December 2, 2019
  • goswifties_prelude-lightning-sketch_20240518_wm 5
    • Featured
    GoSwifties, Beneath And Beyond Celebrity, A Delayed Prelude.
    • May 21, 2024
  • 6
    • Lah!
    • Technology
    Global Space & Technology Convention (GSTC) 2021 Brings Close To 30 Countries And Regions Together to Set Growth Agenda For Asia’s Space Sector; Underscores Confidence In Space As New Engine For Growth
    • June 8, 2021
  • 7
    • Cities
    • Technology
    100 Million Changi Rewards Points And Porsche’s First All-Electric Sports Car To Be Won In Changi Airport’s Brand New ‘Win With Changi’ Shopping Campaign
    • November 3, 2021
  • 8
    • Cities
    • People
    If More Of Us Work From Home After Coronavirus We’ll Need To Rethink City Planning
    • April 28, 2020
  • 9
    • Cities
    SGX RegCo Expands Range Of Enforcement Powers
    • June 25, 2021
  • 10
    • Economy
    • People
    • World Events
    Global Poverty: Coronavirus Could Drive It Up For The First Time Since The 1990s
    • June 17, 2020
  • 11
    • Cities
    Factsheet: Islandwide Cycling Network (ICN) Programme To Improve Safety And Connectivity for all Path Users
    • March 9, 2020
  • 12
    • Lah!
    New Artificial Intelligence Tool Could Speed Up Diagnosis Of Cardiovascular Diseases
    • June 9, 2021
Trending
  • 1
    Apple unveils iPhone 17 Pro and iPhone 17 Pro Max, the most powerful and advanced Pro models ever
    • September 9, 2025
  • 2
    Apple debuts iPhone 17
    • September 9, 2025
  • Fruits and vegetables for cooking. For food processors. 3
    Food Processor: The Swiss Army Knife of the Kitchen – Best All-Around Picks in 2025
    • September 8, 2025
  • 4
    Meet Samsung Galaxy Tab S11 Series: Packing Everything You Expect From a Premium Tablet
    • September 4, 2025
  • 5
    Malaysia’s ‘ASEAN Shenzhen’ needs some significant legal reform to take off — here’s how
    • August 25, 2025
  • French Fries 6
    Air Fryer: The One Cooking Appliance to Rule Them All – Best All-Around Picks in 2025
    • August 22, 2025
  • 7
    Samsung Electronics Debuts Odyssey G7 Monitors, Showcasing Top Games on Its Displays at Gamescom 2025
    • August 20, 2025
  • 8
    HP Cranks Up the Game with Smarter Systems, Cooler Builds, and Gear That Hits Different
    • August 14, 2025
  • 9
    New Trump tariffs: early modelling shows most economies lose – the US more than many
    • August 6, 2025
  • Scuba Diving 10
    Wetsuit or Drysuit? As always, it depends. This quick guide can help you choose.
    • August 2, 2025
Social Links
dotlah! dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
Connecting Dots Across Asia's Tech and Urban Landscape

Input your search keywords and press Enter.